The Tevosol team after winning the DynaLife Health Stream at the 15th VenturePrize Awards

A patent acceptance in the US is the most recent reason to celebrate after a year of successes for Tevosol, a medical device company aiming to increase the number of viable donated organs worldwide. In the last 12 months, Tevosol secured $2 million in financing, won the DynaLIFE Health Stream at the VenturePrize awards, and protected its technology in the US.

Tevosol’s proprietary medical device keeps donated vital organs like hearts and lungs, warm and supplied with oxygen as if they were still in the body, extending the “ex-vivo” (out of body) viability of the organs. The device also resuscitates organs deemed unsuitable, and allows assessment of transplant suitability which has the potential to double or triple the number of available donor organs worldwide.

The recently accepted patent refers to Tevosol’s heart device, and protects the core technology that provides a functional assessment of organs for viability.

A key element to the device (and the patent) is the way the dual centrifugal pumps work. “The proprietary configuration of the pumps is essential to put the heart into functional working mode, and to the ability to assess the quality of the organ,” explains Tevosol CEO Kevin Ens. “That’s the unique way we do things that our competitors are not.”

The company is developing a clinical device incorporating the technology that covers the patent. Kevin expects to have a beta version developed by late 2019, and estimates a Canadian market launch by 2021, and a US launch one year later.

“This is the first foundational patent for us,” says Kevin. “Assuming other applications are granted, we would expect another patent to be issued extending IP protection to different organs, and more patent families that add protection for our other technology. This one is key.”

Tevosol has been a TEC Edmonton client since the beginning of the company’s original business plan in 2014. TEC’s business development services accelerated Tevosol’s growth into an independent company through assistance with market assessment, business planning, patenting, and intellectual property (IP) protection. Tevosol is a TEC Centre tenant, operating out of Enterprise Square in downtown Edmonton.

Posted: Aug 12, 2019

Telebivudine to Abrogate Amyotrophic Lateral Sclerosis

Description Telbivudine Dr. Ted Allison and his team at the University of Alberta have discovered that telbivudine, a blood brain barrier-permeable thymidine analogue approved for treatment of Hepatitis B, is......

Posted: Jun 14, 2019

A Point-of-Care Diagnostic Tool to Replace Chest X-Ray for the Diagnosis of Childhood Pneumonia

Description University of Alberta researchers have discovered a novel set of biomarkers which can be used to diagnose pneumonia in children. The biomarkers include chitinase-3-like-1 (CHI3L1), lipocalin-2 (LCN-2), C-reactive protein......

Posted: Jun 14, 2019

Novel Cell Isolation Method for Bio-engineering Artificial Cartilage

Description University of Alberta researchers have developed a new method to isolate cells from knee joint (meniscus). The isolated cells are non-contractile in nature and do not form scar tissue.......

Posted: Jun 13, 2019

Novel Composite Monolith as a New Solid Phase Extraction Material for Environmental Analysis

Description University of Alberta researchers have developed a new material of a composite silica monolith nested in sponge (SiMNS) for solid phase extraction. The application of the new SiMNS material......

Posted: May 21, 2019

Self Assembling Peptide for Activating Human Mast Cells

Description Researchers at the University of Alberta have developed a novel biomaterial that can activate the body’s own innate immune response and accelerate the wound healing process. This technology may......

Posted: May 21, 2019

An Innocuous Structured Scaffold for Prion Disease Vaccines and Antigens

Description Researchers at the University of Alberta, led by Dr. Holger Wille, have developed a novel strategy for the creation of vaccines and specific antigens for prion protein diseases. Applying......

Posted: May 21, 2019

Spine Mounted Stereotactic System

Description Demonstration of stereotactic setup. An example of a commercially-available micromanipulator is shown. The setup can accommodate any micromanipulator design. Dr. Vivian Mushahwar and her team have developed an image-guided......

Posted: May 15, 2019

Method for the Production of Z-Olefins from 1,3-Dienes

Description Dr. Rylan Lundgren has developed a process for formate-mediated production of Z-olefins (also referred to as cis-alkenes) in the presence of a rhodium-based catalyst. The process is highly selective......

Posted: Apr 3, 2019

A Novel Method to Produce Pitched Kefir for Reducing Cholesterol

Description Researchers at the University of Alberta and TEAGASC have jointly developed a pitched-based method to produce kefir (a fermented milk beverage) that when consumed reduces blood cholesterol levels. The......

Posted: Nov 5, 2018

Novel F-18 Beta-Hydroxybutyric Acid Radiotracers for PET Imaging

Description Researchers at the University of Alberta have synthesized novel beta-hydroxybutyric acid radiotracers for PET imaging using a 3 step radiosynthetic process. The compounds are designed to serve as radiofluorinated......

Posted: Nov 5, 2018

A Novel Method for CryoPreservation of Cells in Monolayers

Description Researchers at the University of Alberta have developed a novel method to cryopreserve cells while adhered in a monolayer configuration. This method can preserve cells on a substrate and......

Posted: Oct 30, 2018

Train-Triggered Alert System for Conditioning and Warning Wildlife

Description Researchers at the University of Alberta have developed a novel, inexpensive, and compact system to alert wildlife to approaching trains, increasing the time available to avoid a collision. Rail-caused......